Featured Posts
Blog
Congress considers micromanaging PBM finances
With the first reconciliation bill behind it, Congress is now looking to reform other aspects of the health care system. Pharmacy Benefit Manager (PBM)…
Blog
Free the Economy podcast: Drug costs and benefits with Sally Pipes
In this week’s episode we cover reforms to the Endangered Species Act, attacks on US tech firms, nuclear power innovation,…
National Review
Telehealth Is Less Promising Than It First Seemed
A key issue facing Congress in its postelection, “lame duck” session is whether to extend regulatory flexibilities expiring at year end that make telehealth services more…
Search Posts
Blog
COVID-19 Vaccine Development Is Testament to the Market’s Ability to Develop Life-Saving New Products
The announcement by drug maker Moderna that preliminary data from its still ongoing trial shows its COVID-19 vaccine is 95 percent effective is extremely encouraging.
Blog
New CEI Report: Making Sure a COVID-19 Vaccine Is Used
One or more COVID-19 vaccines will likely be approved in the next few months. But this scientific achievement may prove to be the easy part.
City Journal
Following The Science — Where?
When doctors meet a patient for a new complaint, we make a list of different possible explanations for the problem—a differential diagnosis—and try to determine…
News Release
CEI Welcomes Senior Fellow with Health Care and Legal Expertise
The Competitive Enterprise Institute is pleased to welcome medical and legal expert Joel M. Zinberg, M.D., J.D. as a senior fellow working on health care…
Blog
How SEC Accounting Regulations Hindered National Stockpile—and Still May Be Doing So
In a new report, CEI experts outline #NeverNeeded regulations that are frustrating responses to the pandemic and its aftermath. Among those is an obscure Securities…
Blog
Getting Rid of #NeverNeeded Regulations Hindering Coronavirus Response
What can Washington do to minimize harm from the coronavirus? Some of the best policy responses are coming not from imposing new regulations, but from…